BRCA2 and breast carcinoma: Even though other studies have also shown a benefit of BRRM for BRCA2 pathogenic variant carriers, a recent observational study did not confirm an increase in breast-cancer-specific survival for BRRM compared to surveillance in this subgroup [70].